Cryptogenic new-onset refractory status epilepticus responded to anti-interleukin-6 treatment
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Neuroimmunology"
DOI: 10.1016/j.jneuroim.2021.577789
Abstract: OBJECTIVE The aim of this case report was to describe a potential anti-interleukin (IL)-6 treatment for cryptogenic new-onset refractory status epilepticus (C-NORSE). BACKGROUND Although an underlying immune-mediated pathogenesis is considered present in some C-NORSE cases,… read more here.
Keywords: anti interleukin; status; interleukin treatment; status epilepticus ... See more keywords
Eczematous eruption during anti‐interleukin 17 treatment of psoriasis: an emerging condition
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Dermatology"
DOI: 10.1111/bjd.17779
Abstract: Major advances in psoriasis pathogenesis gave rise to development of new effective drugs for its treatment. Particularly, biologic drugs revolutionized disease management. TNF-α inhibitors represented the opening available biologic class since 2000. Thus, adverse cutaneous… read more here.
Keywords: eczematous eruption; interleukin treatment; treatment; eruption anti ... See more keywords
TARGETING INTERLEUKIN 17 IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Sign Up to like & getrecommendations! Published in 2018 at "Farmacia"
DOI: 10.31925/farmacia.2018.3.2
Abstract: Interleukin 17 (IL-17) is a family of pro-inflammatory cytokines discovered in 1993. IL-17 drives an important pathogenic pathway in rheumatoid arthritis (RA), leading to and sustaining chronic inflammation. The recognition of this role made IL17… read more here.
Keywords: targeting interleukin; rheumatoid; interleukin treatment; rheumatoid arthritis ... See more keywords